The Institute for Biomolecular Targeting - Equipment Supplement 2022
The Institute for Biomolecular Targeting - Equipment Supplement 2022
批准号:
10581943
负责人:
DEAN R MADDEN
金额:
$23.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-05-15 至 2026-05-31
关键词:
2019-nCoVAddressAntibodiesAreaAutophagocytosisAwardAwarenessBindingBiologicalBusinessesCareer MobilityCenters of Research ExcellenceCommunitiesComplexConsultConsultationsCore FacilityCryoelectron MicroscopyCystic FibrosisDevelopmentDiabetes MellitusDiseaseDrug TargetingEquipmentExtramural ActivitiesFacultyFaculty RecruitmentFinancial SupportFosteringFoundationsFundingFutureGenerationsGoalsGrantHomeImageImmunologicsInfectionInfrastructureInstitutesInvestigationInvestmentsIon ChannelMalignant NeoplasmsMass Spectrum AnalysisMembrane FusionMentorsMetabolic ControlMicroscopeMicroscopyModelingMolecularMolecular TargetNeoplasm MetastasisPathologyPhasePlayPostdoctoral FellowProductionProductivityProgram ReviewsProtein BiochemistryProteinsRecoveryResearchResearch InstituteResearch PersonnelResearch Project GrantsResourcesRespiratory Tract InfectionsRoleSchoolsScientistSeasonsSeriesServicesSignal TransductionSubgroupTargeted ResearchTeacher Professional DevelopmentTechnologyTestingTherapeuticTimeTranslationsVaccinesVirus DiseasesWorkbasecareerclinical practicecohortcommunity buildingcostdiversity and inclusiondrug developmentexperiencefaculty researchfaculty supportfascinateforgingfundamental researchinnovationinstrumentinstrumentationinterestknowledge translationmembermid-career facultymolecular imagingnew technologynovel therapeutic interventionoperationpre-clinicalpreclinical developmentprogramsprotein expressionrecruitsuccesssymposiumtherapeutic targettooltranslational goaltumor progression
中文摘要
达特茅斯生物分子靶向研究所(bioMT)为机制研究注入了
对疾病病理和治疗需求的复杂认识,提高即使是最
基础研究。与此同时,它有助于将机械研究导向长期
例如癌症和感染等复杂疾病的转化目标。在第一阶段,我们的进展是强劲的。
我们的所有六名研究项目负责人(RPL)都获得了两年以上的支持,
经费我们的核心提供独特的蛋白质生物化学资源和“导航员”访问显微镜
全校范围内我们的核心和研讨会创造了一个充满活力和跨学科的社区。这里我们
建议部署COBRE第二阶段和机构计划充实基金,以在此基础上再接再厉,
填补关键空白,使bioMT为过渡到可持续的COBRE独立性做好准备。目标1是提高我们的
一群受资助的bioMT研究人员,以填补我们研究领域的战略角色。我们最近的两个
区域学习计划(3-15个月的支助)将继续进入第二阶段,另外还有两名杰出的新雇员。他们的项目
探索与治疗靶点潜在相关的基本信号传导和免疫机制,
从呼吸道感染到癌症进展和转移,通过共享的科学和
技术兴趣。所有人都接受专门的辅导二人组的指导,以协助职业发展,
独立的校外资金,所有得到支持,从响应科学核心提供国家的,
与bioMT研究项目直接相关的技术。在机构的支持下,我们还将聘请
五名新教师,与我们的发现和利用分子靶点的主题相一致,
选定这些小组是为了加强专题分组。随着RPLs毕业,我们将招募新员工和其他
选管会考虑的潜在候选人。目标二是加强核心设施,
为在第三阶段过渡到COBRE独立性做好准备。核心人员配备齐全,
在第一阶段的仪器上投入了大量资金。我们将根据用户输入,
包括平行蛋白质表达、质谱、高级显微镜和冷冻电镜。费用回收
将为第三阶段的逐步部署制定模式,以实现核心财务独立。目的
3继续丰富我们的社区,包括小型研讨会和试点奖,以促进新的多PI和
方案-项目应用,这将有助于核心可持续性。总的来说,这些目标将利用
经过验证的COBRE战略-初级教师招聘,校外和学术指导,优秀的行政管理
和科学核心支持,以及跨学科社区建设-以提高bioMT的科学影响力,
有针对性的需求领域。这将使我们为过渡到第三阶段供资和最终独立做好准备
作为一个跨学科和全国知名的研究机构,跨越三个学校和10个部门,
达特茅斯,并与当地中心和区域IDEA合作伙伴建立了深厚的联系。
英文摘要
The Dartmouth Institute for Biomolecular Targeting (bioMT) infuses mechanistic investigations with a
sophisticated awareness of disease pathology and therapeutic need, enhancing the quality of even the most
fundamental research. At the same time, it helps orient mechanistic investigations towards long-term
translational goals for complex diseases such as cancer and infections. In phase I, our progress was strong.
All six of our research project leaders (RPL) with more than two years’ support have received R01-equivalent
funding. Our cores provide unique protein biochemistry resources and ‘navigators’ to access microscopes
campus-wide. Our cores and seminars have created a vibrant and interdisciplinary community. Here, we
propose to deploy phase II COBRE and institutional program enrichment funds to build on this foundation and
fill key gaps to prepare bioMT for the transition to sustainable COBRE independence. Aim 1 is to increase our
cohort of funded bioMT investigators to fill strategic roles in our research landscape. Our two most recent
RPLs (3–15 months’ support) are continuing into phase II, joined by two outstanding new hires. Their projects
explore basic signaling and immunological mechanisms with potential relevance to therapeutic targets ranging
from respiratory infections to cancer progression and metastasis, interconnected by shared scientific and
technical interests. All receive guidance from dedicated mentoring dyads to assist in career advancement and
independent extramural funding, and all receive support from responsive scientific cores offering state-of-the-
art technologies directly relevant to their bioMT research projects. With institutional support, we will also hire
five new faculty members, aligned with our theme of discovering and exploiting molecular targets, and
selected to enhance thematic subgroups. As starting RPLs graduate, we will recruit new hires and other
potential candidates for EAC consideration as replacements. Aim 2 is to enhance our core facilities and
prepare them for a transition to COBRE independence during phase III. The cores are fully staffed and have
invested heavily in phase I instrumentation. We will partner to add key new technologies based on user input,
including parallel protein expression, mass spectrometry, advanced microscopy, and cryoEM. Cost-recovery
models will be developed for incremental deployment in phase III to enable core financial independence. Aim
3 continues enriching our community, including mini-symposia and pilot awards to foster new multi-PI and
program-project applications, which will contribute to core sustainability. Overall, these aims will leverage
proven COBRE strategies – junior faculty hiring, extramural and academic mentoring, excellent administrative
and scientific core support, and interdisciplinary community building – to enhance bioMT’s scientific impact in
targeted areas of need. This will prepare us for the transition to phase III funding and ultimate independence
as an interdisciplinary and nationally visible research institute, spanning three schools and 10 departments at
Dartmouth and deeply connected to local centers and regional IDeA partners.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DartCF: The Dartmouth Cystic Fibrosis Research Center
-
批准号:10686303
-
项目类别:
-
资助金额:$120.82万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
Enrichment and Research Administration Core
-
批准号:10686304
-
项目类别:
-
资助金额:$21.04万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
DartCF: The Dartmouth Cystic Fibrosis Research Center
-
批准号:10895149
-
项目类别:
-
资助金额:$47.11万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
DartCF: The Dartmouth Cystic Fibrosis Research Center
-
批准号:10001759
-
项目类别:
-
资助金额:$122.42万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
DartCF: The Dartmouth Cystic Fibrosis Research Center
-
批准号:10678819
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
DartCF: The Dartmouth Cystic Fibrosis Research Center
-
批准号:10474845
-
项目类别:
-
资助金额:$19.73万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
DartCF: The Dartmouth Cystic Fibrosis Research Center
-
批准号:10240591
-
项目类别:
-
资助金额:$120.82万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
Enrichment and Research Administration Core
-
批准号:10001760
-
项目类别:
-
资助金额:$21.04万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
Enrichment and Research Administration Core
-
批准号:10241579
-
项目类别:
-
资助金额:$21.04万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
DartCF: The Dartmouth Cystic Fibrosis Research Center
-
批准号:10895148
-
项目类别:
-
资助金额:$4.22万
-
财政年份:2018
-
负责人:DEAN R MADDEN
-
依托单位:
Research Administration and Mentoring Core
-
批准号:10271746
-
项目类别:
-
资助金额:$64.6万
-
财政年份:2016
-
负责人:DEAN R MADDEN
-
依托单位:
The Institute for Biomolecular Targeting
-
批准号:10460270
-
项目类别:
-
资助金额:$246.0万
-
财政年份:2016
-
负责人:DEAN R MADDEN
-
依托单位:
Research Administration and Mentoring Core
-
批准号:10647697
-
项目类别:
-
资助金额:$90.92万
-
财政年份:2016
-
负责人:DEAN R MADDEN
-
依托单位:
The Institute for Biomolecular Targeting
-
批准号:10271745
-
项目类别:
-
资助金额:$246.0万
-
财政年份:2016
-
负责人:DEAN R MADDEN
-
依托单位:
Research Administration and Mentoring Core
-
批准号:10460271
-
项目类别:
-
资助金额:$64.6万
-
财政年份:2016
-
负责人:DEAN R MADDEN
-
依托单位:
The Institute for Biomolecular Targeting
-
批准号:10647696
-
项目类别:
-
资助金额:$246.0万
-
财政年份:2016
-
负责人:DEAN R MADDEN
-
依托单位:
iTarget: Institute for Biomolecular Targeting
-
批准号:9553073
-
项目类别:
-
资助金额:$13.65万
-
财政年份:2016
-
负责人:DEAN R MADDEN
-
依托单位:
Preclinical development of CFTR stabilizers targeting the CAL PDZ domain
-
批准号:8673464
-
项目类别:
-
资助金额:$48.21万
-
财政年份:2014
-
负责人:DEAN R MADDEN
-
依托单位:
Preclinical development of CFTR stabilizers targeting the CAL PDZ domain
-
批准号:9271954
-
项目类别:
-
资助金额:$49.95万
-
财政年份:2014
-
负责人:DEAN R MADDEN
-
依托单位:
Preclinical development of CFTR stabilizers targeting the CAL PDZ domain
-
批准号:9063125
-
项目类别:
-
资助金额:$48.9万
-
财政年份:2014
-
负责人:DEAN R MADDEN
-
依托单位:
海外基金